InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer
InteRNA Technologies B.V. and VU university medical center in Amsterdam, VUmc, announced the signing of a framework research agreement to develop microRNA (miRNA)-based diagnostics and therapeutics for cancer using InteRNA’s proprietary library of miRNAs.
Under the research collaboration, InteRNA will apply its unique lentiviral-based miRNA overexpression library in multi-parametric, high-throughput screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in leukemia, colon, prostate and head and neck cancer. In addition, diagnostic miRNA profiles will be developed through next-generation sequencing, in combination with InteRNA’s proprietary small RNA bioinformatics pipeline, miR-Intess™, on diverse patient sample sets provided by VUmc.
“The collaboration with InteRNA is another example of our mission to translate our scientific knowledge into products and services that improve healthcare and prevention of disease” said Koen Verhoef, Technology Transfer Officer of VU university medical center.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.